{"prompt": "['Trelagliptin-4002', 'Page 46 of 66', 'Version 1.0', 'November 2, 2016', 'probability that a causal relationship to the study drug or comparative drug cannot be', 'ruled out, although other factors such as underlying disease, complications, or', 'concomitant drugs/treatment are also suspected.', 'An adverse event that does not follow a temporal sequence from administration of', 'Not', 'the study drug or comparative drug. Very likely due to other factors such as', 'related', 'underlying disease, complications, or concomitant drugs/treatment.', '10.1.7 Relationship to study procedures', 'The relationship shall be recorded as \"Yes\" if the principal investigator or the investigator considers', 'that there is reasonable possibility that an adverse event is due to a study procedure. Otherwise, the', 'relationship shall be recorded as \"No.\"', '10.1.8 Date of onset', 'The date of onset of adverse event shall be determined according to the following rules:', 'Adverse events', 'Date of onset', 'Signs, symptoms, diseases', 'The date on which the first signs/symptoms were noted by the', '(diagnoses)', 'study subject and/or the principal investigator or investigator.', 'The date on which a diagnosis was confirmed through a test(s).', 'The date on which a diagnosis was confirmed, even when the', 'Asymptomatic diseases', 'test results indicate an old sign(s) of the disease or an', 'approximate time of its onset.', 'The date on which the first worsening of diseases/symptoms was', 'Exacerbation of complications', 'noted by the study subject and/or the principal investigator or', 'investigator.', 'Onset of a test abnormality', 'after the start of study drug', 'The date on which a clinically significant laboratory abnormality', 'administration or comparative', 'was detected.', 'drug administration', 'Worsening of a baseline test', 'abnormality after the start of', 'The date on which a clear increase/decrease in a laboratory', 'study drug administration or', 'parameter was clinically confirmed based on the time profile of', 'comparative drug', 'the parameter.', 'administration', '10.1.9 Date of resolution', 'The date of resolution of an adverse event is the date on which the study subject recovered', '(including resolution with sequelae). If a study subject died due to the adverse event concerned, it', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 47 of 66', 'Version 1.0', 'November 2, 2016', 'shall be the date of death. The adverse event shall be recorded as \"ongoing\" if the study subject has', 'not yet recovered by the end of the study.', '10.1.10 Actions taken for the study drug or comparative drug', 'Actions taken for the study drug or comparative drug shall be classified or defined as shown below.', 'The study drug or comparative drug is discontinued because of an adverse', 'event (including withdrawal by the study subject at his/her own discretion).', 'Drug withdrawn', 'When the study is discontinued but administration of the study drug or', 'comparative drug is still continued, the classification should be \"Dose not', 'changed.\"', 'The dose was not changed after the onset of the adverse event.', 'Dose not', 'The study drug or comparative drug was discontinued, reduced, or increased', 'because of another adverse event.', 'changed', 'The study drug was discontinued or reduced for a reason other than the', 'adverse event, e.g., inadvertence of the study subject.', 'Unknown', 'It has not been possible to determine what action has been taken because the', 'study subject is lost to follow-up.', 'The administration of the study drug or comparative drug had already been', 'Not Applicable', 'completed or discontinued before the onset of the adverse event.', 'Dose reduced', 'The dose of the study drug or comparative drug is reduced because of an adverse', 'event (including dose reduction by the study subject at his/her own discretion).', 'The dose of the study drug or comparative drug was increased because of the', 'Dose increased', 'adverse event (including dose increase by the study subject at his/her own', 'discretion).', 'If administration of the study drug or comparative drug is suspended (i.e.,', 'Washout', 'interrupted) (including suspension/interruption by the study subject at his/her own', 'discretion) because of the adverse event but resumed thereafter, shall be defined', 'as \"washout\".', '10.1.11 Outcome', 'Outcome of adverse events is classified as follows:', 'Category', 'Criteria', 'Recovered', '- Disappearance or recovery of symptoms and findings', '- Laboratory values returned to normal or baseline', '- The intensity is lowered by one or more stages', '- Symptoms or findings mostly disappeared', 'Improved', '-', 'Laboratory values improved, but have not returned to normal or baseline', '- The study subject died from a cause other than the concerned adverse event', 'while the condition was resolving (recording of the date of death unnecessary)', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}